BMO Capital analyst Gary Nachman downgraded Viatris to Market Perform from Outperform with a price target of $14, down from $16. The company is progressing well with its strategic initiatives to create additional value, but the stock could be range-bound pending execution on the next phase of its evolution, the analyst tells investors in a research note. The firm sees a lack of visibility on the timing of Viatris’s next divestitures and uncertainty around the peak potential for its newly acquired Eye Care franchise.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTRS: